TY - JOUR
T1 - Prognostic Impact of Major Receptor Tyrosine Kinase Expression in Gastric Cancer
AU - Kurokawa, Yukinori
AU - Matsuura, Nariaki
AU - Kawabata, Ryohei
AU - Nishikawa, Kazuhiro
AU - Ebisui, Chikara
AU - Yokoyama, Yuhki
AU - Shaker, Mohammed Nouri
AU - Hamakawa, Takuya
AU - Takahashi, Tsuyoshi
AU - Takiguchi, Shuji
AU - Mori, Masaki
AU - Doki, Yuichiro
N1 - Funding Information:
ACKNOWLEDGMENT This study was supported by Chugai Pharmaceutical.
Publisher Copyright:
© 2014, Society of Surgical Oncology.
PY - 2014
Y1 - 2014
N2 - Background: Various kinds of molecular targeted drugs to inhibit receptor tyrosine kinases (RTKs) have been recently developed. The relationship between the expression status of major RTKs and prognosis in gastric cancer remains unclear. We conducted a multicenter study to evaluate the prognostic impact of the expression of epidermal growth factor receptor (EGFR), c-Met, platelet-derived growth factor receptor (PDGFR), and c-Kit in gastric cancer.Methods: This study included 153 gastric cancer patients who underwent gastrectomy at 9 institutions between 2000 and 2006. Expression status of EGFR, c-Met, PDGFR, and c-Kit were evaluated with immunohistochemistry (IHC) centrally. Overall survival based on RTK expression status was statistically compared. Cox multivariate analysis was conducted to adjust for potentially confounding factors.Conclusions: Our multicenter study indicated that IHC expression of 4 RTKs had some prognostic impact and that c-Kit–positive status may be a significant indicator of good prognosis in gastric cancer patients.Results: The positive rates for EGFR, c-Met, PDGFR, and c-Kit were 14.4, 24.8, 41.2, and 11.1 %, respectively. Significant interactions with expression status were observed for pathological N stage with EGFR; HER2-status with c-Met; tumor location, histology, and pathological N stage with PDGFR; and no examined variables with c-Kit. Concomitant HER2 positivity was observed for 0.7 % of tumors positive for EGFR, 3.9 % for c-Met, 4.6 % for PDGFR, and 1.3 % for c-Kit. There were some differences in overall survival between patients with or without RTK expression, but only c-Kit expression showed a significant survival difference in Cox multivariate analysis (P = 0.046).
AB - Background: Various kinds of molecular targeted drugs to inhibit receptor tyrosine kinases (RTKs) have been recently developed. The relationship between the expression status of major RTKs and prognosis in gastric cancer remains unclear. We conducted a multicenter study to evaluate the prognostic impact of the expression of epidermal growth factor receptor (EGFR), c-Met, platelet-derived growth factor receptor (PDGFR), and c-Kit in gastric cancer.Methods: This study included 153 gastric cancer patients who underwent gastrectomy at 9 institutions between 2000 and 2006. Expression status of EGFR, c-Met, PDGFR, and c-Kit were evaluated with immunohistochemistry (IHC) centrally. Overall survival based on RTK expression status was statistically compared. Cox multivariate analysis was conducted to adjust for potentially confounding factors.Conclusions: Our multicenter study indicated that IHC expression of 4 RTKs had some prognostic impact and that c-Kit–positive status may be a significant indicator of good prognosis in gastric cancer patients.Results: The positive rates for EGFR, c-Met, PDGFR, and c-Kit were 14.4, 24.8, 41.2, and 11.1 %, respectively. Significant interactions with expression status were observed for pathological N stage with EGFR; HER2-status with c-Met; tumor location, histology, and pathological N stage with PDGFR; and no examined variables with c-Kit. Concomitant HER2 positivity was observed for 0.7 % of tumors positive for EGFR, 3.9 % for c-Met, 4.6 % for PDGFR, and 1.3 % for c-Kit. There were some differences in overall survival between patients with or without RTK expression, but only c-Kit expression showed a significant survival difference in Cox multivariate analysis (P = 0.046).
UR - http://www.scopus.com/inward/record.url?scp=84939885266&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84939885266&partnerID=8YFLogxK
U2 - 10.1245/s10434-014-3690-x
DO - 10.1245/s10434-014-3690-x
M3 - Article
C2 - 24743909
AN - SCOPUS:84939885266
SN - 1068-9265
VL - 21
SP - 584
EP - 590
JO - Annals of Surgical Oncology
JF - Annals of Surgical Oncology
IS - 4
ER -
